Ranchi News Desk

Hemophilia A Market Insights and Treatment Market by DelveInsight

 Breaking News
  • No posts were found

Hemophilia A Market Insights and Treatment Market by DelveInsight

April 23
18:44 2021
Hemophilia A Market Insights and Treatment Market by DelveInsight

 

Hemophilia A Market” report has been added to DelveInsight

 

Hemophilia A Disease Overview

Hemophilia A is a genetic bleeding disorder in which an individual lacks or has low levels of proteins named clotting factor VIII.

 

Get Free Sample Copy Now- https://www.delveinsight.com/sample-request/hemophilia-a2030-market

 

 

Hemophilia A Regions Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

 

Hemophilia A Market Companies

  • Novo Nordisk
  • Bayer
  • Octapharma
  • Takeda
  • Sanofi/Sobi
  • CSL Behring
  • Bayer
  • Octapharma
  • Pfizer
  • Genentech
  • HEMA Biologics/LFB Pharmaceuticals
  • And many others

 

Hemophilia A Drugs

  • Esperoct (N8-GP; Turoctocog alfa pegol)
  • Jivi (formerly BAY94-9027)
  • Wilate
  • Adynovate (Adynovi; BAX 855)
  • Eloctate [Antihemophilic Factor (Recombinant), Fc Fusion Protein; Elocta (efmoroctocog alfa)]
  • Afstyla (Lonoctocog alfa)
  • Kovaltry (BAY 81-8973)
  • Nuwiq (simoctocog alfa)

 

Hemophilia A Treatment Market

The mainstay treatment option has long been FVIII replacement therapy. Initially, FVIII replacement was accomplished by donated whole blood, subsequently by plasma and currently by recombinant human FVIII (rFVIII) replacement therapies, which revolutionized the treatment of Hemophilia A.

 

Hemophilia A Market Report

About 30% of severe hemophilia A patients develop neutralizing anti-FVIII alloantibodies (inhibitors), which render the FVIII replacement ineffective. The standard of care therapy for patients with inhibitors is to induce immune tolerance with high-dose, high-frequency FVIII and treatment with bypassing agents (e.g. recombinant activated factor VII such as NovoSeven, FEIBA).

 

Hemophilia A Market Research

As per DelveInsight estimation, the future of hemophilia treatment is continuing to trend toward extended half-life therapies as well as more novel approaches including siRNA, bi-specific antibodies and gene therapy. If these therapies are ultimately successfully commercialized they have the potential to transform the current standard of care for hemophilia A patients

 

Hemophilia A Market Industry

Hemophilia A is a life-long condition. Currently, there is no cure, but researchers are actively engaged in finding the cure through gene therapy. One hope is that by inserting a healthy version of the defective blood factor gene, a person with hemophilia will be able to produce reasonable amounts of a factor on their own.

 

Hemophilia A Market Trends

Generally, Hemophilia A patients are provided with “On Demand” and “Prophylaxis” treatment. But Prophylaxis treatment option has gained importance in comparison to the on-demand treatment options. Currently, the major treatment options of Hemophilia A are:

Currently, the major treatment options of Hemophilia A are Factor Replacement Concentrates, the source of which is either recombinant DNA technology or Human plasma-derive, and Bypassing agents. Moreover, this is an off-label treatment option, wherein Desmopressin Acetate (DDAVP) and Adjunctive therapies are also available for the management of Hemophilia A.

 

Hemophilia A Market Highlights

  • In the coming years, Hemophilia A market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Hemophilia A R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition       
  • Major players are involved in developing therapies for Hemophilia A. Launch of emerging therapies will significantly impact the Hemophilia A market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Hemophilia A
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

 

Get Free Sample Copy Now- https://www.delveinsight.com/sample-request/hemophilia-a2030-market

 

 

Table of content

1. Key Insights

2. Executive Summary of Hemophilia A

3. Competitive Intelligence Analysis for Hemophilia A

4. Hemophilia A: Market Overview at a Glance

5. Hemophilia A: Disease Background and Overview

6. Patient Journey

7. Hemophilia A Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Hemophilia A Treatment

11. Marketed Products

12. Emerging Therapies

13. Hemophilia A: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Hemophilia A

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/

Related Articles